combination therapy with glp-1 receptor agonist and sglt2 inhibitor Without Inhibitors in Patients With Type 2 Diabetes Combining GLP-1 Receptor Agonists and

The global obesity GLP-1 market size accounted for USD 8.21 billion in 2025 and is predicted to increase from USD 10.12 billion in 2026 to approximately USD 66.57 billion by 2035, expanding at a CAGR of 23.28% from 2026 to 2035

Camilleri M, Parkman HP, Shafi MA, Abell TL, Gerson L

Funding This study was supported by a grant of Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare (HF20C0002), The Basic Science Research Program through the National Research Foundation of Korea, funded by The Ministry of Education (2018R1A6A1A03025108), and the Research Fund of The Catholic University of Korea (2023)

The consent is not adequate, Caplan said